FiercePharma10d
Novo Nordisk slashes prices of additional insulin products but not until 2026
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
As insulin shortages persist, what diabetes patients can do
Manufacturing delays will cause the Novo Nordisk's Fiasp vials to be in short supply through October, a spokesperson said.
pharmaphorum3d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin ... which is available in vial form or as a disposable pen.
Medscape16y
Diabetes Care -- Insulin Delivery in a Changing World
The main problems with initiation and maintenance of insulin therapy, along with solutions to these concerns, are outlined below. Solution: Rapid-acting analogs ... with a vial and syringe ...
Business Insider India1y
There's something odd about the way insulin prices change
A 10 ml vial of Sanofi's long-acting insulin Lantus first hit the US market ... an increase of 1,124% over 20 years. Novo Nordisks's Novolog first hit the market in August 2001 at $39.75, and ...